1310340-58-9
1310340-58-9
Chemical Structure
VBY-825
- CAS No.: 1310340-58-9
- Formula:C23H29F4N3O5S
- Molecular Weight:535.55
IUPAC Name: (S)-N-cyclopropyl-3-((R)-3-((cyclopropylmethyl)sulfonyl)-2-(((S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl)amino)propanamido)-2-oxopentanamide
InChIKey: PPUXXDKQNAHHON-BJLQDIEVSA-N
SMILES: CC[C@H](NC([C@@H](N[C@@H](C1=CC=C(F)C=C1)C(F)(F)F)CS(=O)(CC2CC2)=O)=O)C(C(NC3CC3)=O)=O
Biological Activity: VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VBY-825 | 99.67% | VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Elie BT, et al. Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. Biochimie. 2010 Nov;92(11):1618-24. [Content Brief]
- [2]. Umaretiya, et al. Cathepsin Inhibitor, VBY-825, Attenuates Bone Cancer Induced Pain in Mice. The University of Arizona.
- [3]. Laura Orellano, et al. Therapeutic potential of VBY-825 in MSU crystal-induced NLRP3 inflammasome activation. The Journal of Immunology. 2024. 212 (1_Supplement): 0957_5533.
